Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin
Executive SummaryThe attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting
You may also be interested in...
Portola says that it does not expect it will need to do a second Phase III study to get FDA approval for betrixaban, after missing major endpoint in APEX, but analysts have doubts.
A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.